Search This Blog

Wednesday, July 17, 2019

Halozyme bags $5M milestone from argenx on start of efgartigimod study

The first patient has been dosed in a Phase 1 clinical trial evaluating the safety, pharmacokinetics and pharmacodynamics of a subcutaneously administered formulation of argenx SE’s (NASDAQ:ARGX) efgartigimod (ARGX-113) based on Halozyme Therapeutics’ (NASDAQ:HALO) ENHANZE drug delivery technology.
The event triggers a $5M milestone payment to HALO.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)